# Altered Mental Status â€“ RRT Protocol with Virtua Voorhees Addenda

**Primary Guideline:** American Academy of Neurology (AAN) Practice Guidelines for Evaluation of Cognitive Impairment and Dementia
**Official Source:** https://www.aan.com/Guidelines/
**Supporting Guidelines:**
- Emergency Neurological Life Support (ENLS) 2025 Guidelines
- American Delirium Society Clinical Practice Guidelines 2023
- Society for Academic Emergency Medicine (SAEM) Altered Mental Status Guidelines

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["AMS Recognition<br/>Assess ABCs + GCS"] --> B["Immediate Stabilization<br/>Glucose + Vitals + O2"]
    
    B --> C{"Blood Glucose<br/><60 or >400 mg/dL?"}
    
    C -->|YES| D["Treat Glucose Emergency<br/>D50 or Insulin Protocol"]
    C -->|NO| E["Focused History<br/>+ Neurologic Exam"]
    
    D --> E
    E --> F{"Focal Neurologic<br/>Deficits Present?"}
    
    F -->|YES| G["Stroke Protocol<br/>Code Stroke Activation"]
    F -->|NO| H{"Fever or<br/>Meningeal Signs?"}
    
    G --> I["CT Head STAT<br/>Neurology Consult"]
    H -->|YES| J["CNS Infection Workup<br/>Empiric Antibiotics"]
    H -->|NO| K{"Recent Drug/Toxin<br/>Exposure History?"}
    
    I --> L["Advanced Stroke Care<br/>Consider Intervention"]
    J --> M["Lumbar Puncture<br/>(after CT if no ICP)"]
    K -->|YES| N["Empiric Reversal<br/>Naloxone/Flumazenil"]
    K -->|NO| O["Metabolic Workup<br/>Comprehensive Labs"]
    
    M --> P["Meningitis/Encephalitis<br/>Treatment Protocol"]
    N --> Q{"Response to<br/>Reversal Agents?"}
    O --> R{"Metabolic Cause<br/>Identified?"}
    
    Q -->|YES| S["Continue Antidote<br/>Monitor Recovery"]
    Q -->|NO| T["Expanded Differential<br/>Advanced Testing"]
    R -->|YES| U["Treat Specific<br/>Metabolic Disorder"]
    R -->|NO| T
    
    L --> V["ICU/Stroke Unit<br/>Specialized Care"]
    P --> V
    S --> W["Monitor Recovery<br/>Disposition Planning"]
    T --> X["MRI/EEG/LP<br/>Specialist Consult"]
    U --> W
    
    X --> Y["Neurology/Psychiatry<br/>Advanced Evaluation"]
    W --> Z["Disposition Based<br/>on Underlying Cause"]
    V --> Z
    Y --> Z
    
    style A fill:#ffcccc
    style B fill:#ffe6cc
    style G fill:#fff2cc
    style J fill:#ccffcc
    style N fill:#e6ccff
    style V fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ AMS Recognition & Initial Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ§  ALTERED MENTAL STATUS RRT            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Recognition criteria:                â”‚
â”‚ â€¢ Acute change from baseline           â”‚
â”‚ â€¢ Altered consciousness/awareness       â”‚
â”‚ â€¢ Confusion, disorientation            â”‚
â”‚ â€¢ Abnormal behavior patterns           â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ ABC Assessment (Priority #1):        â”‚
â”‚ â€¢ Airway: Protect if GCS â‰¤8           â”‚
â”‚ â€¢ Breathing: Assess respiratory status â”‚
â”‚ â€¢ Circulation: Check perfusion/BP      â”‚
â”‚ â€¢ Disability: GCS calculation          â”‚
â”‚                                         â”‚
â”‚ ğŸ“ˆ Glasgow Coma Scale:                  â”‚
â”‚ â€¢ Eye opening (1-4)                    â”‚
â”‚ â€¢ Verbal response (1-5)                â”‚
â”‚ â€¢ Motor response (1-6)                 â”‚
â”‚ â€¢ Total score /15                      â”‚
â”‚                                         â”‚
â”‚ [Next: Immediate stabilization â–¶]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1 â€“ Immediate Stabilization (Node B â†’ C)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš€ IMMEDIATE STABILIZATION PROTOCOL     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¬ Glucose assessment (STAT):           â”‚
â”‚ â€¢ Fingerstick glucose immediately      â”‚
â”‚ â€¢ Critical: <60 or >400 mg/dL          â”‚
â”‚ â€¢ Don't delay for lab confirmation     â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Vital signs assessment:              â”‚
â”‚ â€¢ Temperature (fever = infection?)     â”‚
â”‚ â€¢ Blood pressure (HTN emergency?)      â”‚
â”‚ â€¢ Pulse oximetry (hypoxia?)            â”‚
â”‚ â€¢ Respiratory rate (CO2 retention?)    â”‚
â”‚                                         â”‚
â”‚ ğŸ’¨ Oxygen support:                      â”‚
â”‚ â€¢ Apply if SpO2 <94%                   â”‚
â”‚ â€¢ Consider airway protection if needed â”‚
â”‚ â€¢ IV access establishment              â”‚
â”‚                                         â”‚
â”‚ [Next: Glucose emergency check â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Recognition]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Glucose Emergency Treatment (Node D â†’ E)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¯ GLUCOSE EMERGENCY MANAGEMENT          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ”½ Hypoglycemia (<60 mg/dL):            â”‚
â”‚ â€¢ D50: 25-50mL IV bolus                â”‚
â”‚ â€¢ Thiamine 100mg IV (before glucose!)  â”‚
â”‚ â€¢ Repeat glucose in 15 minutes         â”‚
â”‚ â€¢ Continuous glucose monitoring        â”‚
â”‚                                         â”‚
â”‚ ğŸ”º Severe hyperglycemia (>400 mg/dL):   â”‚
â”‚ â€¢ Normal saline 1-2L bolus             â”‚
â”‚ â€¢ Regular insulin 0.1 units/kg/hr      â”‚
â”‚ â€¢ Check ketones and ABG               â”‚
â”‚ â€¢ Electrolyte monitoring q2h           â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Thiamine protocol (alcohol risk):    â”‚
â”‚ â€¢ Always give before glucose           â”‚
â”‚ â€¢ Prevents Wernicke encephalopathy     â”‚
â”‚ â€¢ 100mg IV push                        â”‚
â”‚                                         â”‚
â”‚ [Next: Focused neurologic exam â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Stabilization]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3 â€“ Focused History & Neurologic Exam (Node E â†’ F)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©º NEUROLOGIC EXAMINATION               â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Essential history (from witnesses):  â”‚
â”‚ â€¢ Baseline mental status               â”‚
â”‚ â€¢ Time course of change                â”‚
â”‚ â€¢ Recent medications/changes            â”‚
â”‚ â€¢ Substance use history                â”‚
â”‚ â€¢ Recent illness/procedures            â”‚
â”‚                                         â”‚
â”‚ ğŸ” Focused neurologic exam:             â”‚
â”‚ â€¢ Mental status: Orientation, attentionâ”‚
â”‚ â€¢ Cranial nerves: Pupils, eye movementsâ”‚
â”‚ â€¢ Motor: Strength, tone, reflexes      â”‚
â”‚ â€¢ Sensory: Response to stimulation     â”‚
â”‚ â€¢ Coordination: Finger-to-nose         â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Key assessments:                     â”‚
â”‚ â€¢ FAST-ED stroke screen                â”‚
â”‚ â€¢ Meningeal signs (neck stiffness)     â”‚
â”‚ â€¢ Signs of increased ICP               â”‚
â”‚                                         â”‚
â”‚ [Next: Focal deficit assessment â–¶]     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Glucose Treatment]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Stroke Protocol Activation (Node G â†’ I)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ STROKE PROTOCOL ACTIVATION           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Focal neurologic findings present:   â”‚
â”‚ â€¢ Unilateral weakness                  â”‚
â”‚ â€¢ Facial droop                         â”‚
â”‚ â€¢ Speech abnormalities                 â”‚
â”‚ â€¢ Visual field defects                 â”‚
â”‚ â€¢ Gaze deviation                       â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Immediate actions:                   â”‚
â”‚ â€¢ Code Stroke activation               â”‚
â”‚ â€¢ Sevaro Teleneurology: 856-247-3098   â”‚
â”‚ â€¢ CT head STAT (within 25 minutes)     â”‚
â”‚ â€¢ NPO status                           â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Time targets:                        â”‚
â”‚ â€¢ Door-to-CT: <25 minutes              â”‚
â”‚ â€¢ Door-to-needle: <60 minutes          â”‚
â”‚ â€¢ NIHSS assessment                     â”‚
â”‚                                         â”‚
â”‚ [Next: Advanced stroke care â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Neurologic Exam]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4B â€“ CNS Infection Evaluation (Node J â†’ M)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¦  CNS INFECTION ASSESSMENT             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸŒ¡ï¸ Fever + AMS indicators:              â”‚
â”‚ â€¢ Temperature >38Â°C (100.4Â°F)          â”‚
â”‚ â€¢ Neck stiffness (nuchal rigidity)     â”‚
â”‚ â€¢ Photophobia                          â”‚
â”‚ â€¢ Headache with AMS                    â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Empiric antibiotic therapy:          â”‚
â”‚ â€¢ Don't delay for lumbar puncture!     â”‚
â”‚ â€¢ Age <50: Ceftriaxone 2g IV q12h      â”‚
â”‚            + Vancomycin 15-20mg/kg     â”‚
â”‚ â€¢ Age â‰¥50: Add Ampicillin 2g IV q4h    â”‚
â”‚ â€¢ HSV risk: Add Acyclovir 10mg/kg q8h  â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Dexamethasone protocol:              â”‚
â”‚ â€¢ 0.15mg/kg IV q6h Ã— 4 days            â”‚
â”‚ â€¢ Give before or with first antibiotic â”‚
â”‚                                         â”‚
â”‚ [Next: Lumbar puncture evaluation â–¶]   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Neurologic Exam]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4C â€“ Toxicologic Assessment (Node K â†’ N)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â˜ ï¸ TOXICOLOGIC CAUSE EVALUATION         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ” High-risk medication/substance history:â”‚
â”‚ â€¢ Opioid medications or illicit use    â”‚
â”‚ â€¢ Benzodiazepine medications           â”‚
â”‚ â€¢ Alcohol use disorder                 â”‚
â”‚ â€¢ New psychiatric medications          â”‚
â”‚ â€¢ Recent anesthesia/procedures         â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Clinical toxidromes:                 â”‚
â”‚ â€¢ Opioids: Pinpoint pupils, â†“RR       â”‚
â”‚ â€¢ Anticholinergic: Dry, flushed, dilatedâ”‚
â”‚ â€¢ Cholinergic: SLUDGE symptoms         â”‚
â”‚ â€¢ Sympathomimetic: Agitation, â†‘HR/BP   â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Laboratory studies:                  â”‚
â”‚ â€¢ Comprehensive toxicology screen       â”‚
â”‚ â€¢ Acetaminophen and salicylate levels  â”‚
â”‚ â€¢ Ethanol level                        â”‚
â”‚                                         â”‚
â”‚ [Next: Empiric reversal agents â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Neurologic Exam]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Advanced Stroke Care (Node L â†’ V)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ§  ADVANCED STROKE MANAGEMENT           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“¸ CT head interpretation:              â”‚
â”‚ â€¢ Rule out intracranial hemorrhage     â”‚
â”‚ â€¢ Early ischemic changes               â”‚
â”‚ â€¢ Mass effect or midline shift         â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Treatment considerations:             â”‚
â”‚ â€¢ IV thrombolysis (TNK preferred)      â”‚
â”‚ â€¢ Mechanical thrombectomy evaluation   â”‚
â”‚ â€¢ Blood pressure management           â”‚
â”‚ â€¢ Antiplatelet therapy timing         â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Specialist coordination:             â”‚
â”‚ â€¢ Neurology consultation              â”‚
â”‚ â€¢ Interventional neuroradiology       â”‚
â”‚ â€¢ Intensive care unit                 â”‚
â”‚                                         â”‚
â”‚ âœ… STROKE PROTOCOL ACTIVE              â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Stroke Activation]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5B â€“ Lumbar Puncture Protocol (Node M â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’‰ LUMBAR PUNCTURE EVALUATION           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… LP indications:                      â”‚
â”‚ â€¢ Suspected meningitis/encephalitis     â”‚
â”‚ â€¢ Subarachnoid hemorrhage (CT negative) â”‚
â”‚ â€¢ Fever + AMS without clear source     â”‚
â”‚                                         â”‚
â”‚ ğŸš« LP contraindications:                â”‚
â”‚ â€¢ Signs of increased ICP               â”‚
â”‚ â€¢ Coagulopathy (INR >1.5, plt <50K)    â”‚
â”‚ â€¢ Infection at puncture site           â”‚
â”‚ â€¢ Hemodynamic instability              â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š CSF analysis priorities:             â”‚
â”‚ â€¢ Cell count with differential         â”‚
â”‚ â€¢ Glucose and protein                  â”‚
â”‚ â€¢ Bacterial culture and gram stain     â”‚
â”‚ â€¢ HSV PCR, cryptococcal antigen        â”‚
â”‚                                         â”‚
â”‚ [Next: Meningitis treatment â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: CNS Infection]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Empiric Reversal Agents (Node N â†’ Q)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”„ EMPIRIC ANTIDOTE ADMINISTRATION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Naloxone (opioid reversal):          â”‚
â”‚ â€¢ Dose: 0.4-2mg IV/IM/IN               â”‚
â”‚ â€¢ Start low to avoid withdrawal        â”‚
â”‚ â€¢ Duration: 30-90 minutes              â”‚
â”‚ â€¢ May need repeat dosing               â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Flumazenil (benzodiazepine reversal): â”‚
â”‚ â€¢ Dose: 0.2mg IV over 30 seconds       â”‚
â”‚ â€¢ Max: 1mg total dose                  â”‚
â”‚ â€¢ âš ï¸ CAUTION: Seizure risk in chronic usersâ”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Thiamine (always give):               â”‚
â”‚ â€¢ 100mg IV before any glucose          â”‚
â”‚ â€¢ Prevents Wernicke encephalopathy     â”‚
â”‚ â€¢ Especially important with alcohol    â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Toxicologic Assessment]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6B â€“ Metabolic Workup (Node O â†’ R)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ§ª COMPREHENSIVE METABOLIC EVALUATION   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Essential laboratory studies:        â”‚
â”‚ â€¢ Complete metabolic panel             â”‚
â”‚ â€¢ Liver function tests                 â”‚
â”‚ â€¢ Ammonia level                        â”‚
â”‚ â€¢ Thyroid function (TSH, free T4)      â”‚
â”‚ â€¢ Vitamin B12 and folate               â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Additional tests if indicated:       â”‚
â”‚ â€¢ Arterial blood gas                   â”‚
â”‚ â€¢ Magnesium and phosphorus             â”‚
â”‚ â€¢ Cortisol (random or stimulation)     â”‚
â”‚ â€¢ Urinalysis and culture               â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Common metabolic causes:             â”‚
â”‚ â€¢ Hyponatremia (<120 mEq/L)            â”‚
â”‚ â€¢ Severe renal failure (uremia)        â”‚
â”‚ â€¢ Hepatic encephalopathy (â†‘NH3)        â”‚
â”‚ â€¢ Thyroid disorders                    â”‚
â”‚                                         â”‚
â”‚ [Next: Specific treatment â–¶]           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Neurologic Exam]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7A â€“ Meningitis Treatment Protocol (Node P â†’ V)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¦  MENINGITIS/ENCEPHALITIS TREATMENT    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Antimicrobial therapy:               â”‚
â”‚ â€¢ Continue empiric antibiotics started â”‚
â”‚ â€¢ Adjust based on CSF results          â”‚
â”‚ â€¢ Duration: 7-21 days depending on organismâ”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Anti-inflammatory therapy:           â”‚
â”‚ â€¢ Dexamethasone: Continue if started   â”‚
â”‚ â€¢ Reduces complications in bacterial   â”‚
â”‚ â€¢ Not indicated for viral meningitis   â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ Supportive care:                     â”‚
â”‚ â€¢ ICU monitoring if severe             â”‚
â”‚ â€¢ Seizure precautions                  â”‚
â”‚ â€¢ ICP monitoring if indicated          â”‚
â”‚ â€¢ Isolation as appropriate             â”‚
â”‚                                         â”‚
â”‚ âœ… CNS INFECTION PROTOCOL ACTIVE       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Lumbar Puncture]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7B â€“ Antidote Response Assessment (Node Q)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š REVERSAL AGENT RESPONSE              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Positive response indicators:         â”‚
â”‚ â€¢ Improved level of consciousness      â”‚
â”‚ â€¢ Better GCS score                     â”‚
â”‚ â€¢ Normalized vital signs               â”‚
â”‚ â€¢ Appropriate responses                â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Partial/no response indicators:       â”‚
â”‚ â€¢ Minimal improvement                  â”‚
â”‚ â€¢ Mixed clinical picture               â”‚
â”‚ â€¢ Other causes likely                  â”‚
â”‚                                         â”‚
â”‚ â“ Adequate response to reversal?       â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Continue monitoring & support â”‚
â”‚ ğŸ”˜ NO â†’ Expanded differential workup   â”‚
â”‚                                         â”‚
â”‚ ğŸ’¡ Consider:                            â”‚
â”‚ â€¢ Multiple ingestions                  â”‚
â”‚ â€¢ Delayed absorption                   â”‚
â”‚ â€¢ Structural brain pathology           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8A â€“ Specific Metabolic Treatment (Node U â†’ W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¯ METABOLIC DISORDER TREATMENT          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ§‚ Hyponatremia correction:             â”‚
â”‚ â€¢ Rate: 6-8 mEq/L per 24 hours         â”‚
â”‚ â€¢ 3% saline if severe symptoms         â”‚
â”‚ â€¢ Monitor closely for CPM              â”‚
â”‚                                         â”‚
â”‚ ğŸ«˜ Hepatic encephalopathy:               â”‚
â”‚ â€¢ Lactulose 30mL PO q2h until BM      â”‚
â”‚ â€¢ Rifaximin 550mg PO BID               â”‚
â”‚ â€¢ Protein restriction contraindicated  â”‚
â”‚                                         â”‚
â”‚ ğŸ¦‹ Thyroid emergencies:                  â”‚
â”‚ â€¢ Myxedema coma: T4 + T3 + steroids    â”‚
â”‚ â€¢ Thyroid storm: Methimazole + beta-blockersâ”‚
â”‚                                         â”‚
â”‚ [Next: Monitor recovery â–¶]             â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Metabolic Workup]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8B â€“ Expanded Differential Testing (Node T â†’ X)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ ADVANCED DIAGNOSTIC EVALUATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ§  Advanced neuroimaging:               â”‚
â”‚ â€¢ MRI brain with and without contrast  â”‚
â”‚ â€¢ MR angiography if vascular suspected â”‚
â”‚ â€¢ CT perfusion if stroke possible      â”‚
â”‚                                         â”‚
â”‚ âš¡ Electroencephalogram (EEG):           â”‚
â”‚ â€¢ Rule out non-convulsive seizures     â”‚
â”‚ â€¢ Continuous monitoring if indicated   â”‚
â”‚ â€¢ Metabolic encephalopathy patterns    â”‚
â”‚                                         â”‚
â”‚ ğŸ’‰ Additional lumbar puncture:          â”‚
â”‚ â€¢ If CNS infection still suspected     â”‚
â”‚ â€¢ Autoimmune/paraneoplastic workup     â”‚
â”‚ â€¢ Cytology if malignancy suspected     â”‚
â”‚                                         â”‚
â”‚ [Next: Specialist consultation â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Response Assessment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9A â€“ Recovery Monitoring (Node W â†’ Z)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ RECOVERY MONITORING & SUPPORT        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Progress indicators:                 â”‚
â”‚ â€¢ Improving GCS score                  â”‚
â”‚ â€¢ Return to baseline orientation       â”‚
â”‚ â€¢ Stable vital signs                   â”‚
â”‚ â€¢ Resolved metabolic abnormalities     â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Ongoing management:                  â”‚
â”‚ â€¢ Continue specific treatments         â”‚
â”‚ â€¢ Monitor for complications            â”‚
â”‚ â€¢ Prevent further episodes             â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Discharge planning:                  â”‚
â”‚ â€¢ Medication reconciliation            â”‚
â”‚ â€¢ Follow-up appointments               â”‚
â”‚ â€¢ Family education                     â”‚
â”‚ â€¢ Safety precautions                   â”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Specific Treatment]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9B â€“ Specialist Consultation (Node Y â†’ Z)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ‘¨â€âš•ï¸ SPECIALIST CONSULTATION              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ§  Neurology consultation:              â”‚
â”‚ â€¢ Complex altered mental status        â”‚
â”‚ â€¢ Seizure evaluation                   â”‚
â”‚ â€¢ Encephalitis management              â”‚
â”‚                                         â”‚
â”‚ ğŸ§  Psychiatry consultation:             â”‚
â”‚ â€¢ Conversion disorder                  â”‚
â”‚ â€¢ Psychotic episodes                   â”‚
â”‚ â€¢ Catatonia                            â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Additional specialists:              â”‚
â”‚ â€¢ Endocrinology (metabolic causes)     â”‚
â”‚ â€¢ Infectious disease (CNS infections)  â”‚
â”‚ â€¢ Toxicology (complex poisonings)      â”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Advanced Testing]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 10 â€“ Disposition Planning (Node Z - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ DISPOSITION & FOLLOW-UP PLANNING     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Disposition options:                 â”‚
â”‚                                         â”‚
â”‚ ğŸ”´ ICU admission:                       â”‚
â”‚ â€¢ GCS <9 or declining                  â”‚
â”‚ â€¢ Hemodynamic instability             â”‚
â”‚ â€¢ Requiring intensive monitoring       â”‚
â”‚ â€¢ Post-stroke intervention             â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¡ Telemetry/Step-down:                 â”‚
â”‚ â€¢ Stable but requires monitoring       â”‚
â”‚ â€¢ Medication titration needed          â”‚
â”‚ â€¢ Cardiac arrhythmia risk              â”‚
â”‚                                         â”‚
â”‚ ğŸŸ¢ Medical floor:                       â”‚
â”‚ â€¢ Stable, identified cause             â”‚
â”‚ â€¢ Minimal ongoing intervention         â”‚
â”‚ â€¢ Social/family support needed         â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Follow-up coordination:              â”‚
â”‚ â€¢ Neurology: 1-2 weeks if indicated    â”‚
â”‚ â€¢ Primary care: Within 1 week          â”‚
â”‚ â€¢ Specialist referrals as needed       â”‚
â”‚                                         â”‚
â”‚ âœ… AMS PROTOCOL COMPLETE               â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Treatment Pathways]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES ALTERED MENTAL STATUS ADDENDA

### **Enhanced RRT Response Program:**
- **Rapid Response Team:** Immediate multidisciplinary activation including critical care, neurology access
- **Point-of-Care Testing:** Bedside glucose, ABG, and basic metabolic panels available
- **Stroke Integration:** Seamless transition to Code Stroke protocol with teleneurology support
- **Quality Metrics:** Time to glucose check, GCS documentation, appropriate workup completion

### **Neurologic Assessment Optimization:**
**Glasgow Coma Scale Integration:**
- **Digital scoring:** Automated calculation with trend monitoring
- **Baseline comparison:** Electronic record integration for change documentation
- **Alert thresholds:** Automatic notification for significant changes (â‰¥2 point drop)

**Stroke Protocol Integration:**
- **FAST-ED screening:** Incorporated into initial RRT assessment
- **Code Stroke activation:** Direct communication with Sevaro Teleneurology (856-247-3098)
- **Time-critical imaging:** STAT CT head within 25 minutes of recognition

### **Advanced Diagnostic Capabilities:**
**Laboratory Services:**
- **Point-of-care glucose:** Available on all RRT carts
- **STAT laboratory:** Comprehensive metabolic panel results within 60 minutes
- **Toxicology screening:** Comprehensive panel including newer synthetic drugs

**Imaging Integration:**
- **CT head:** Available 24/7 with immediate interpretation
- **MRI brain:** Urgent studies available with neurologist consultation
- **EEG monitoring:** Continuous monitoring capability for seizure evaluation

### **Pharmacologic Intervention Protocols:**
**Empiric Treatment Guidelines:**
- **Thiamine administration:** 100mg IV before any glucose administration
- **Naloxone protocol:** Weight-based dosing with graduated titration
- **Antibiotic timing:** Empiric therapy within 60 minutes of CNS infection suspicion

**Reversal Agent Safety:**
- **Flumazenil cautions:** Detailed screening for chronic benzodiazepine use
- **Naloxone monitoring:** Observation for withdrawal symptoms and re-sedation
- **Antidote availability:** Emergency antidotes readily available in pharmacy

### **Delirium Assessment Integration:**
**CAM-ICU Protocol:**
- **Structured assessment:** Standardized tool for delirium screening
- **Risk factor identification:** Medication review, infection screening
- **Non-pharmacologic interventions:** Sleep hygiene, reorientation, mobility

**Delirium Prevention:**
- **Medication review:** Identify and minimize deliriogenic medications
- **Environmental modifications:** Noise reduction, lighting optimization
- **Family involvement:** Encourage familiar face presence

### **Stroke Network Integration:**
**Sevaro Teleneurology Partnership:**
- **24/7 availability:** 856-247-3098 with <45 second response time
- **Video consultation:** Real-time neurologic assessment capability
- **Decision support:** Thrombolysis and thrombectomy recommendations

**Transfer Protocols:**
- **Advanced stroke centers:** Direct transfer arrangements for interventional therapy
- **Mobile stroke units:** Coordination with regional mobile stroke response
- **Quality tracking:** Door-to-needle and transfer times monitoring

### **CNS Infection Management:**
**Antibiotic Stewardship:**
- **Empiric protocols:** Age and risk-factor based antibiotic selection
- **Steroid timing:** Dexamethasone administration with or before first antibiotic dose
- **Culture optimization:** CSF, blood, and urine cultures before antimicrobials

**Lumbar Puncture Safety:**
- **Contraindication screening:** Automated checklist for safety assessment
- **Coagulation monitoring:** INR and platelet count verification
- **Post-procedure monitoring:** Standardized observation protocol

### **Metabolic Emergency Protocols:**
**Glucose Management:**
- **Hypoglycemia protocol:** D50 administration with thiamine pretreatment
- **DKA/HHS recognition:** Automated screening for ketoacidosis
- **Continuous monitoring:** Glucose trend analysis with alert parameters

**Electrolyte Correction:**
- **Hyponatremia management:** Careful correction rate monitoring (6-8 mEq/L/24h)
- **Critical value alerts:** Automated notification for life-threatening abnormalities
- **Specialist consultation:** Endocrinology availability for complex cases

### **Quality Improvement Integration:**
**Performance Metrics:**
- **Recognition time:** Goal <5 minutes from RRT activation to AMS assessment
- **Glucose check:** Goal <3 minutes from patient contact
- **Stroke activation:** Goal <15 minutes for appropriate candidates
- **Antibiotic administration:** Goal <60 minutes for suspected CNS infection

**Documentation Standards:**
- **Baseline comparison:** Electronic health record integration for mental status changes
- **Timeline documentation:** Precise timing of symptom onset and progression
- **Response tracking:** Medication administration and clinical response documentation

### **Family Communication Protocol:**
- **Information gathering:** Structured interview for baseline function and recent changes
- **Progress updates:** Regular communication regarding evaluation and treatment
- **Discharge planning:** Family education on ongoing care needs and follow-up requirements

## REFERENCE GUIDELINES
- **2023 American Academy of Neurology Practice Guidelines for Cognitive Assessment**
- **2025 Emergency Neurological Life Support (ENLS) Altered Mental Status Guidelines**
- **2023 American Delirium Society Clinical Practice Guidelines**
- **Virtua Health System Altered Mental Status Protocol v2025**

**This comprehensive protocol integrates current evidence-based approaches to altered mental status evaluation with rapid diagnostic capabilities, stroke network integration, and advanced therapeutic interventions optimized for the Virtua Voorhees clinical environment.**
